Randomized Trial Of Standard Chemotherapy Alone Or Combined With Atezolizumab As Adjuvant Therapy For Patients With Stage III Colon Cancer And Deficient DNA Mismatch Repair
This randomized phase III trial studies combination chemotherapy and atezolizumab to see how
well it works compared with combination chemotherapy alone in treating patients with stage
III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in
combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as
atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving
combination chemotherapy with atezolizumab may work better than combination chemotherapy
alone in treating patients with colon cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.